Clinical Trials Logo

Clinical Trial Summary

The use of agonist of GnRH (aGnRH) trigger to avoid ovarian hyperstimulation syndrome is nowadays widely used. The action of the aGnRH in the hypophysis triggers an LH and FSH surge, which mimicks the natural surge that occurs in the middle of a natural cycle, and thus being able to elicit the ovulation. However, in some patients the aGnRH trigger ends in a poor oocyte recuperation, and that has led some physicians to measure the LH surge after the aGnRH trigger to check its effectiveness. Even though there is still some discrepancy about the exact cut-off value for a proper LH surge 12h after the aGnRH trigger, most of the published papers report the value of 15UI/L as an adequate threshold under which the results of the pick-up are suboptimal. Other authors even report a value of 52UI/L to predict a decrease in oocyte retrieval and maturity rate and a value of 15UI/L to predict a dramatic decrease in the results. Some of the abovementioned studies report that the basal LH value or the LH value on the day of the trigger could also be predictive of suboptimal responses. Additionally, some authors have tried to "rescue" the suboptimal patients with a retrigger of hCG, or they have compared those suboptimal responders with patients triggered with both aGnRH and low doses of hCG. In both cases the addition of hCG seems to improve the results. Most of the scientific bibliography available so far is based on infertile patients undergoing IVF treatments, while in some papers both IVF patients and egg donors have been analyzed. The current study involves exclusively oocyte donation cycles, where the final aim is to identify donors at a high risk of a suboptimal response, and to potentially improve results by potentially adding low doses of hCG (1000 UI).


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms

  • Poor Response to Ovulation Induction

NCT number NCT05109403
Study type Observational
Source Clínica EUGIN
Contact
Status Completed
Phase
Start date February 1, 2021
Completion date February 10, 2022

See also
  Status Clinical Trial Phase
Not yet recruiting NCT05298657 - The Angiotensin-Melatonin Axis in Poor and Hyper Responders for IVF Treatment
Suspended NCT04066478 - Does DHEA IVF Outcomes in Poor Responders? Phase 2/Phase 3
Withdrawn NCT05405686 - Effect of LH Supplementation on the Endometrial Gene Expression Profile in Poor Ovarian Responders Phase 4
Recruiting NCT05181748 - Autologous Platelet Rich Plasma Intraovarian Infusion for Poor Responders Phase 2/Phase 3
Recruiting NCT04485819 - Optimal Embryonic Stage for Transfer in Poor Responders
Recruiting NCT05780632 - A Prospective Observational Study of Biomarkers for a Personalised IVF Treatment